Amphivena Therapeutics, Inc. is a private immuno-oncology company that is developing selective T cell engagers for the treatment of hematologic and solid tumors.  AMV564, our lead molecule, has demonstrated novel clinical activity by rapidly and selectively eliminating leukemic blasts and immature, granulocytic and monocytic myeloid derived suppressor cells (MDSC) while sparing normal myeloid cells, including neutrophils and monocytes.  AMV564 has an excellent safety profile that enables competitive approaches, including combination therapy, and provides a unique opportunity to explore the impact of MDSC depletion in cancer.    

Press Releases

Amphivena Reports Data on Phase 1 Study of AMV564 at ASH Annual Meeting - December 9, 2019

Rationale for Expansion of AMV564 into Solid Tumors - November 7, 2019

Amphivena Initiates Solid Tumor Clinical Trial - October 16, 2019

Latest News

Clinical Data for Amphivena Therapeutics’ Lead Program to be presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting - May 14, 2020